Ramão Souza de Deus Junior1, Andressa Leite Ferraz2, Silvia Aparecida Oesterreich3, Wanderlei Onofre Schmitz4, Marcia Midori Shinzato5. 1. Faculdade de Ciências da Saúde, Universidade Federal da Grande Dourados, Dourados, MS, Brasil. Electronic address: ramaojunior@ufgd.edu.br. 2. Hospital Universitário de Dourados, Universidade Federal da Grande Dourados, Dourados, MS, Brasil. 3. Faculdade de Ciências da Saúde, Universidade Federal da Grande Dourados, Dourados, MS, Brasil; Universidad de León, León, Espanha. 4. Hospital Universitário de Dourados, Universidade Federal da Grande Dourados, Dourados, MS, Brasil; Universidade Estadual de Londrina, Londrina, PR, Brasil. 5. Faculdade de Ciências da Saúde, Universidade Federal da Grande Dourados, Dourados, MS, Brasil; Hospital Universitário de Dourados, Universidade Federal da Grande Dourados, Dourados, MS, Brasil; Universidade de São Paulo, São Paulo, SP, Brasil.
Abstract
OBJECTIVE: To identify risk factors for cardiovascular disease in patients with Rheumatoid Arthritis (RA). MATERIAL AND METHODS: A descriptive cross-sectional study with 71 patients with established RA. The instruments used were: DAS-28, HAQ and SF-36, and the following parameters were determined: the erythrocyte sedimentation rate, capillary blood glucose; total cholesterol (TC) and its fractions, thyroid hormones, antinuclear antibodies (ANA), rheumatoid factor (RF) and antibodies against citrullinated proteins (ACPAs). Patients were classified into groups HAQ ≤ 1 (mild dysfunction) and HAQ > 1 (moderate and severe dysfunction) and, according to the HAQ scores, in groups treated with corticosteroids (CS) and without CS. RESULTS: 9 patients were male and 62 female with mean age and duration of disease of 53.45 (± 10.7) and 9.9 (± 8.6), respectively. RF was positive in 52 (76%), ACPAs in 54 (76.1%) and ANA in 12 (16.9%). Thirty-six patients (50.7%) had systemic hypertension, 9 (12.68%) diabetes mellitus, 16 (22.5%) hypothyroidism, 33 (46.5%) dyslipidemia and 8 (11.27%) were smokers. The results of TC >240 were found in 53.8% for group HAQ >1 (26) and in 24.4% for group HAQ ≤ 1 (45) (p=0.020). These groups did not differ as to presence of comorbidities or drug treatment. Triglyceride levels >200 for the group with CS (42.4%) versus without CS (18.42%) were significant (p=0.025). CONCLUSION: An association of increased TC and triglycerides with results of HAQ ≤ 1 and with CS use was noted, reinforcing the importance of screening risk factors associated with cardiovascular disease in RA.
OBJECTIVE: To identify risk factors for cardiovascular disease in patients with Rheumatoid Arthritis (RA). MATERIAL AND METHODS: A descriptive cross-sectional study with 71 patients with established RA. The instruments used were: DAS-28, HAQ and SF-36, and the following parameters were determined: the erythrocyte sedimentation rate, capillary blood glucose; total cholesterol (TC) and its fractions, thyroid hormones, antinuclear antibodies (ANA), rheumatoid factor (RF) and antibodies against citrullinated proteins (ACPAs). Patients were classified into groups HAQ ≤ 1 (mild dysfunction) and HAQ > 1 (moderate and severe dysfunction) and, according to the HAQ scores, in groups treated with corticosteroids (CS) and without CS. RESULTS: 9 patients were male and 62 female with mean age and duration of disease of 53.45 (± 10.7) and 9.9 (± 8.6), respectively. RF was positive in 52 (76%), ACPAs in 54 (76.1%) and ANA in 12 (16.9%). Thirty-six patients (50.7%) had systemic hypertension, 9 (12.68%) diabetes mellitus, 16 (22.5%) hypothyroidism, 33 (46.5%) dyslipidemia and 8 (11.27%) were smokers. The results of TC >240 were found in 53.8% for group HAQ >1 (26) and in 24.4% for group HAQ ≤ 1 (45) (p=0.020). These groups did not differ as to presence of comorbidities or drug treatment. Triglyceride levels >200 for the group with CS (42.4%) versus without CS (18.42%) were significant (p=0.025). CONCLUSION: An association of increased TC and triglycerides with results of HAQ ≤ 1 and with CS use was noted, reinforcing the importance of screening risk factors associated with cardiovascular disease in RA.
Authors: Mayara Costa de Camargo; Bruna Cipriano Almeida Barros; Izabela Fulone; Marcus Tolentino Silva; Miriam Sanches do Nascimento Silveira; Iara Alves de Camargo; Silvio Barberato-Filho; Fernando de Sá Del Fiol; Luciane Cruz Lopes Journal: Front Pharmacol Date: 2019-09-11 Impact factor: 5.810